Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Novel CAR T-cell approaches — including off-the-shelf allogeneic and in vivo therapies — are showing striking early results in relapsed/refractory multiple myeloma. CB-011, an allogeneic BCMA-directed therapy, hit a 92% overall response rate in BCMA-naive patients, while the in vivo agent KLN-1010 achieved 100% responses across three dose levels. These next-gen approaches could slash wait times, cut costs, and sidestep the logistical hurdles of today's approved therapies.
The two FDA-approved CAR T-cell therapies for relapsed/refractory multiple myeloma — cilta-cel and ide-cel — have been game-changers, but they come with real-world challenges: long wait times, complex manufacturing, lymphodepletion requirements, and eventual relapse. Researchers are now pushing the field forward with two promising next-generation approaches: allogeneic (off-the-shelf) and in vivo CAR T-cell therapies.
CB-011, an allogeneic BCMA-directed CAR T engineered with "immune cloaking," delivered impressive phase 1 results in BCMA-naive myeloma patients. Meanwhile, in vivo CAR T therapy — where a viral vector is infused directly into the patient, who then generates their own CAR T cells — eliminates the need for leukapheresis or lymphodepletion entirely. Early data on KLN-1010, tested in the inMMyCAR study, showed a perfect response rate across all dose levels.
By the Numbers
Why it matters: If durability and safety hold up in larger trials, these approaches could dramatically expand access to CAR T-cell therapy — reaching patients who can't wait for custom manufacturing or who've already been exposed to BCMA-targeted treatments.
